alexa Celiac disease | Spain | PDF | PPT| Case Reports | Symptoms | Treatment

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Recommended Conferences

Read more

Recommended Journals

Relevant Topics

Celiac Disease

  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger
  • Celiac disease

    Celiac disease is an immune reaction to eating gluten, a protein found in wheat, barley and rye. If you have celiac disease, eating gluten triggers an immune response in your small intestine. Over time, this reaction produces inflammation that damages the small intestine's lining and prevents absorption of some nutrients (malabsorption).

  • Celiac disease

    In addition to digestive problems, other signs and symptoms of celiac disease include: Anemia, usually resulting from iron deficiency Loss of bone density (osteoporosis) or softening of bone (osteomalacia) Itchy, blistery skin rash (dermatitis herpetiformis) Damage to dental enamel Headaches and fatigue Nervous system injury, including numbness and tingling in the feet and hands, and possible problems with balance Joint pain Reduced functioning of the spleen (hyposplenism) Acid reflux and heartburn

  • Celiac disease

    1. Confirmed diagnosis. 2. Treatment begins. Treatment is a prescription - lifelong elimination of "gluten". You are going to be healthier. No surgery is required. No medication is required. The only known treatment for celiac disease to date is a gluten-free diet.

  • Celiac disease

    A total of 974 new cases of CD were included. The median age at diagnosis was 2.3 years; 39.5% of CD diagnoses occurred in the first 2 years, 42% between 2 and 6, and 18.4% from 6 to 15. Total number of cases in each age group was 385, 409, and 180, respectively. Regarding clinical presentation 70.9% showed classical symptoms, 21.9% were nonclassical, and 7% were asymptomatic. A total of 95.7% of 931, 94.7% of 611, and 86.7% of 651 children tested positive, respectively, for immunoglobulin A (IgA) anti-transglutaminase type 2 antibodies, IgA endomysial antibodies, and IgA anti-gliadin antibodies. Villous atrophy was observed in 92.4% and increased intraepithelial lymphocytes with crypt hyperplasia in 3.3%. Of the children, 55% had normal growth, and 3.4% were overweight.

Expert PPTs

Speaker PPTs

 

High Impact List of Articles

Conference Proceedings

adwords